Thanks for bringing this to our attention.
We asked our Research Team about the finding and they shared this:
These are exciting findings, the results so far look very positive. However, it is early days for this particular potential drug as the research so far has only been done in worms.
“Targeting the clumps of alpha synuclein, called Lewy bodies, that form inside cells affected by Parkinson’s is a strategy a number of researchers are working on at the moment. And a number of studies can be found at different stages of the research pipeline.
“While early stage studies may take a few years to reach clinical trials in people, there are other potential drugs that aim to stop alpha synuclein clumps forming already in or expected to enter clinical trials, such as NPT 200-11 and Posiphen. Additionally, there are several active clinical trials of various immunotherapies that aim to target this protein to prevent its spread.
“We continue to fund research into targeting alpha-synuclein to slow or stop Parkinson’s in the hope that one or more of the strategies currently being developed will be successful. We also keep an eye on developments in this field and are working on an alpha-synuclein blog post at the moment to do a roundup of all the clinical trials in this area. You can find our research blog at parkinsons.org.uk/blog
I hope you find this information useful.